CoChat

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Open access
Aroda, Vanita R., Rosenstock, Julio, Terauchi, Yasuo, Altuntas, Yuksel, Lalic, Nebojsa M., Morales Villegas, Enrique C., Jeppesen, Ole K., Christiansen, Erik, Hertz, Christin L., Haluzík, Martin, PIONEER 1 Investigators, Belkacem, Krim, Chiali, Nabil, Bourezane, Samia, Guermaz, Rachida, Popivanov, Plamen, Lefterov, Ivaylo, Tankova, Tsvetalina, Penchev, Ivan, Koskova, Martina, Hudcova, Miroslava, Vesela, Alica, Rancova, Anna, Haluzik, Martin, Kiyosue, Arihiro, Matsuoka, Osamu, Inoue, Satoshi, Terauchi, Yasuo, Fukushima, Yasushi, Ide, Yumiko, Violante Ortiz, Rafael Margarito, Morales Villegas, Enrique, Golovach, Albina, Alpenidze, Diana, Frolova, Elena, Zhdanova, Elena, Ruyatkina, Ludmila, Ershova, Olga, Samoilova, Yulia, Zyangirova, Svetlana, Lalic, Katarina, Lalic, Nebojsa, Beljic Zivkovic, Teodora, Ataoglu, Esra, Bakiner, Okan, Dayan, Akin, Sargin, Mehmet, Mert, Meral, Adas, Mine, Tabak, Omur, Altuntas, Yuksel, Murray, Alexander, Iranmanesh, Ali, Schlau, Aron, Wieskopf, Bram, Snyder, Brian, Griffin, Carl, Fogarty, Charles, Lovell, Charles, Allison, Dale, Fitz-Patrick, David, Grant, David, Klonoff, David, Williams, Dwayne, Armas, Eddie, Palace, Eileen, Ruoff, Gary, Martinez, Gilbert, Perez, Gilberto, Bays, Harold, Tatu, Horia, Maynard, James, Cedeno, Jeanne-Elyse, Aroda, Vanita, Park, Jean, Sutton, Jennefer, Pouzar, Joe, Bertsch, John, Condit, Jonathan, Serje, Jorge, Cabaccan, Josel, Risser, Joseph, Frias, Juan, Rosenstock, Julio, Sivalingam, Kanagaratnam, Maw, Kelli, Hanson, Lenita, Billings, Liana, Connery, Lisa, Juarez, Mario, Lillestol, Michael, Fraser, Neil, Beckett, Paul, Wade, Ralph, Gaona, Raul, Jackson, Richard, DeLuca, Robert, Alpizar, Sady, Herring, Sharon, Stringam, Stanley, Bauer, Steven, Gangi, Sumana, Sligh, Teresa, Jarrett, Wentworth, Fitzgibbons, William · 2019 · Diabetes Care

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-0749

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 23 references

Cited by

Items 301–400 of 538

Metadata

Authors
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
Affiliations
  • Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  • Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Cardiometabolic Research Center, Aguascalientes, Mexico
  • Novo Nordisk (Denmark) (DK)
  • Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
Venue
Diabetes Care
Published
2019-06-11
Volume
42
Issue
9
Pages
1724-1732
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2951522032
Cited by
493
References
23
Citations by year
2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
FWCI
36.10
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
MeSH terms
Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.